These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 28068521)
21. Coronary heart disease in people infected with HIV. Malvestutto CD; Aberg JA Cleve Clin J Med; 2010 Aug; 77(8):547-56. PubMed ID: 20682517 [TBL] [Abstract][Full Text] [Related]
22. Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection. Kelesidis T; Currier JS Endocrinol Metab Clin North Am; 2014 Sep; 43(3):665-84. PubMed ID: 25169560 [TBL] [Abstract][Full Text] [Related]
23. Dyslipidemia in HIV patients. Tungsiripat M; Aberg JA Cleve Clin J Med; 2005 Dec; 72(12):1113-20. PubMed ID: 16392725 [TBL] [Abstract][Full Text] [Related]
24. Lipid metabolism in treated HIV Infection. Dubé MP; Cadden JJ Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837 [TBL] [Abstract][Full Text] [Related]
25. Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy. Mandal A; Mukherjee A; Lakshmy R; Kabra SK; Lodha R Indian J Pediatr; 2016 Mar; 83(3):226-31. PubMed ID: 26334860 [TBL] [Abstract][Full Text] [Related]
26. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. de Larrañaga GF; Wingeyer SD; Puga LM; Alonso BS; Benetucci JA Eur J Clin Microbiol Infect Dis; 2006 Feb; 25(2):98-103. PubMed ID: 16477441 [TBL] [Abstract][Full Text] [Related]
27. The nurse practitioner's role in managing dyslipidemia and other cardiovascular risk factors in HIV-infected patients: impact of antiretroviral therapy. Willard S J Assoc Nurses AIDS Care; 2006; 17(1):7-17. PubMed ID: 16686080 [TBL] [Abstract][Full Text] [Related]
28. Common adverse effects of antiretroviral therapy for HIV disease. Reust CE Am Fam Physician; 2011 Jun; 83(12):1443-51. PubMed ID: 21671545 [TBL] [Abstract][Full Text] [Related]
30. Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics. Tarr PE; Rotger M; Telenti A Pharmacogenomics; 2010 Apr; 11(4):587-94. PubMed ID: 20350140 [TBL] [Abstract][Full Text] [Related]
31. Dyslipidemia and its Treatment in HIV Infection. Grunfeld C Top HIV Med; 2010; 18(3):112-8. PubMed ID: 20921577 [TBL] [Abstract][Full Text] [Related]
35. HIV medications: an update and review of metabolic complications. Hester EK Nutr Clin Pract; 2012 Feb; 27(1):51-64. PubMed ID: 22307491 [TBL] [Abstract][Full Text] [Related]
36. HIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular risk. Zou W; Berglund L Prev Cardiol; 2007; 10(2):96-103; quiz 104-5. PubMed ID: 17392622 [No Abstract] [Full Text] [Related]
37. The metabolic syndrome and HIV infection. Li Vecchi V; Maggi P; Rizzo M; Montalto G Curr Pharm Des; 2014; 20(31):4975-5003. PubMed ID: 24320034 [TBL] [Abstract][Full Text] [Related]
38. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Falutz J Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086 [TBL] [Abstract][Full Text] [Related]
39. The cardiovascular and metabolic complications of HIV infection. Krishnaswamy G; Chi DS; Kelley JL; Sarubbi F; Smith JK; Peiris A Cardiol Rev; 2000; 8(5):260-8. PubMed ID: 11174904 [TBL] [Abstract][Full Text] [Related]
40. Management of dyslipidemia in patients with human immunodeficiency virus. Shalit P Rev Cardiovasc Med; 2014; 15 Suppl 1():S38-46. PubMed ID: 24987862 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]